CNS

PSI is a leading full-service CRO with 800+ staff in Europe (Eastern, Central, Western), the USA and Latin America.

PSI is known and respected for consistently securing fast patient enrollment into clinical trials of all sizes and levels of complexity, across a broad range of indications.

PSI has successfully performed Phase II/III studies in the following CNS indications:

Alzheimer's disease
CVD (including TIA and stroke)
Depression
Diabetic neuropathy
Epilepsy
Generalized anxiety disorder
Insomnia
Narcolepsy
Multiple sclerosis
Parkinson's disease
Post-stroke spasticity
Schizophrenia
Sexual dysfunction
Smoking cessation

PSI has developed a database of 1000+ CNS sites, grouped by indication, as listed below:

CNS Indication	# Sites
Alzheimer's disease	80
CVD (including TIA and stroke)	137
Depression	103
Diabetic neuropathy	159
Epilepsy	61
Generalized anxiety disorder	73
Insomnia	27
Multiple sclerosis	100
Narcolepsy	40
Parkinson's disease	80
Post-stroke spasticity	40
Schizophrenia	115
Sexual dysfunction	9
Smoking cessation	52
	1,076

PSI employs physicians as full-time monitors and project managers, most of whom are board certified specialists, including neurologists, psychiatrists, and pediatric psychiatrists.